Treatment of dyskinesia

Abstract

The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.

1 - 21 . (Cancel).  
     
     
         22 . A method for the treatment of dyskinesia comprising administering to a person or animal in need of said treatment an amount of a compound which inhibits selectively mu opioid receptor activity or activation sufficient to effect said treatment.  
     
     
         23 . The method according to  claim 22  wherein said dyskinesia is associated with movement disorders.  
     
     
         24 . The method according to  claim 23 , wherein said dyskinesia is associated with parkinsonism.  
     
     
         25 . The method according to  claim 24  wherein the parkinsonism is idiopathic Parkinson's disease or post-encephalitic parkinsonism.  
     
     
         26 . The method according to  claim 24  wherein the parkinsonism results from head injury, the treatment of schizophrenia, drug intoxication or manganese poisoning.  
     
     
         27 . The method according to  claim 22  wherein said dyskinesia is associated with Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease, the treatment of schizophrenia, drug intoxication or manganese poisoning.  
     
     
         28 . The method according to  claim 22  wherein said dyskinesia arises as a side-effect of a therapeutic agent.  
     
     
         29 . The method according to  claim 28 , wherein said dyskinesia is associated with agents used to treat movement disorders.  
     
     
         30 . The method according to  claim 22 , wherein the compound is a mu opioid receptor antagonist.  
     
     
         31 . The method according to  claim 22 , wherein said amount is between 0.1 mgs/kg/day and 500 mgs/kg/day.  
     
     
         32 . The method according to  claim 22 , wherein said amount is between 0.3 mgs/kg/day and 100 mgs/kg/day.  
     
     
         33 . The method according to  claim 22 , wherein said amount is about 10 mgs/kg/day.  
     
     
         34 . The method according to  claim 22 , wherein said compound is present in a composition in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle, or liposome.  
     
     
         35 . The method according to  claim 22  wherein the composition is in a form suitable for oral administration.  
     
     
         36 . The method according to  claim 22  wherein said treatment is prophylactic treatment.